Kidney Fibrosis: Lock out SIRT4
Chronic kidney disease is estimated to affect over 10% of the global population (Kovesdy, 2022). Its most common feature is kidney fibrosis, which is characterized by the accumulation of extracellular matrix proteins in tissues, causing structural damage that can impair the function of the kidneys (Huang et al., 2023).
Previous work revealed that complex mechanisms and protein mediators drive kidney fibrosis, including the protein TGF-β1, which plays a vital role in promoting the expression of pro-fibrotic genes. TGF-β1 acts through a well-established signaling pathway that eventually activates a set of three transcription factors – Smad2, Smad3 and Smad4 – which collectively move from the cytoplasm to the nucleus where they promote the transcription of pro-fibrotic genes (Meng et al., 2016). The transport of molecules from the cytoplasm to the nucleus occurs continuously in cells throughout the body and must be tightly controlled to prevent aberrant traffic that can drive disease.
However, directly inhibiting TGF-β1 signaling to prevent kidney fibrosis is not an ideal therapeutic strategy due to the potential adverse effects of disrupting other biological processes involving TGF-β1. Therefore, a greater understanding of the mechanisms underlying TGF-β1-induced fibrosis is required to identify alternative approaches. Now, in eLife, Lin Kang, Zhen Liang, Shu Yang and colleagues – including Guangyan Yang, Jiaqing Xiang and Xiaoxiao Yang as joint first authors – report how unusual TGF-β1-driven translocation of the protein Sirtuin 4 into the nucleus contributes to the progression of kidney fibrosis (Yang et al., 2024).
Sirtuin 4 (also known as SIRT4 for short) is normally located in the mitochondria. However, Yang et al. (who are based at the First Affiliated Hospital of Southern University of Science and Technology and Hefei University of Technology) found increased amounts of SIRT4 in the nuclei of kidney cells from patients with chronic kidney disease. Similarly, they also discovered elevated levels of nuclear SIRT4 in the kidneys of mice that had been injured during surgery to induce kidney fibrosis experimentally.
Intriguingly, Yang et al. found that deleting the gene for SIRT4 significantly reduced the extent of kidney fibrosis in mice following an injury; this occurred either globally throughout the body or specifically in the epithelial cells lining tubules in the kidney. Consistent with this finding, overexpressing the gene in the same cells markedly enhanced the extent of kidney fibrosis. Taken together, these results suggest that abnormal nuclear accumulation of SIRT4 contributes to kidney fibrosis.
To investigate the mechanism underlying SIRT4-mediated fibrosis, Yang et al. carried out experiments in human kidney tubule epithelial cells to identify which proteins interact with SIRT4 upon TGF-β1 treatment. Interestingly, SIRT4 interacted with several proteins that localized in the nucleus, including U2AF2 (short for U2 small nuclear RNA auxiliary factor 2). This protein plays an important role in assembling the molecular machinery known as a spliceosome, which removes unnecessary parts of pre-mRNA to form the mature mRNA that is translated into a protein (Zorio and Blumenthal, 1999; Agrawal et al., 2016).
Yang et al. found that TGF-β1 treatment induced SIRT4 to remove acetyl groups from U2AF2. This allowed U2AF2 to splice the pre-mRNA of a pro-fibrotic protein called CCN2 (short for cell communication network 2), causing expression of this protein to increase. Together, these findings identify the SIRT4-U2AF2-CCN2 axis as a novel mechanism of TGF-β1-induced kidney fibrosis (Figure 1).
Yang et al. next set out to explore how SIRT4 translocates from the mitochondria to the nucleus upon TGF-β1 treatment. The experiments showed that TGF-β1-induced release of SIRT4 from mitochondria occurs through pores formed by protein polymers known as BAX and BAK, which are located in the outer membrane of mitochondria (Cosentino and García-Sáez, 2017). Screening using a variety of protein inhibitors demonstrated that in order to translocate, SIRT4 must be phosphorylated by enzymes known as ERK1 and ERK2. This modification allows SIRT4 to bind to a nuclear-transport receptor called importin α1, which moves the protein into the nucleus. Finally, Yang et al. treated mice with anti-SIRT4 antibodies that only inhibit expression of SIRT4 in the nucleus, and found this targeted disruption could sufficiently alleviate surgery-induced kidney fibrosis.
These findings open an exciting avenue for the development of a novel therapeutic strategy against kidney fibrosis: to lock the ‘bad guy’ – SIRT4 – out of the nuclei of kidney cells. It is conceivable that in the future, small molecules that hinder SIRT4 from interacting with ERK1/2 or importin α1 could be screened or synthesized to treat kidney fibrosis. However, nuclear SIRT4 may play beneficial roles in other cells and tissues (Zeng et al., 2018), thus further clinical studies are needed to evaluate the safety of such a strategy.
References
-
An extended U2AF(65)-RNA-binding domain recognizes the 3’ splice site signalNature Communications 7:10950.https://doi.org/10.1038/ncomms10950
-
Bax and Bak pores: Are we closing the circle?Trends in Cell Biology 27:266–275.https://doi.org/10.1016/j.tcb.2016.11.004
-
Kidney fibrosis: from mechanisms to therapeutic medicinesSignal Transduction and Targeted Therapy 8:129.https://doi.org/10.1038/s41392-023-01379-7
-
Epidemiology of chronic kidney disease: an update 2022Kidney International Supplements 12:7–11.https://doi.org/10.1016/j.kisu.2021.11.003
-
TGF-β: the master regulator of fibrosisNature Reviews Nephrology 12:325–338.https://doi.org/10.1038/nrneph.2016.48
Article and author information
Author details
Publication history
Copyright
© 2024, Zhao and Zhou
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 218
- views
-
- 35
- downloads
-
- 0
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Cell Biology
The epigenetic reader SntB was identified as an important transcriptional regulator of growth, development, and secondary metabolite synthesis in Aspergillus flavus. However, the underlying molecular mechanism is still unclear. In this study, by gene deletion and complementation, we found SntB is essential for mycelia growth, conidial production, sclerotia formation, aflatoxin synthesis, and host colonization. Chromatin immunoprecipitation sequencing (ChIP-seq) and RNA sequencing (RNA-seq) analysis revealed that SntB played key roles in oxidative stress response of A. flavus, influencing related gene activity, especially catC encoding catalase. SntB regulated the expression activity of catC with or without oxidative stress, and was related to the expression level of the secretory lipase (G4B84_008359). The deletion of catC showed that CatC participated in the regulation of fungal morphogenesis, reactive oxygen species (ROS) level, and aflatoxin production, and that CatC significantly regulated fungal sensitive reaction and AFB1 yield under oxidative stress. Our study revealed the potential machinery that SntB regulated fungal morphogenesis, mycotoxin anabolism, and fungal virulence through the axle of from H3K36me3 modification to fungal virulence and mycotoxin biosynthesis. The results of this study shed light into the SntB-mediated transcript regulation pathways of fungal mycotoxin anabolism and virulence, which provided potential strategy to control the contamination of A. flavus and its aflatoxins.
-
- Cell Biology
Aging is associated with a number of physiologic changes including perturbed circadian rhythms; however, mechanisms by which rhythms are altered remain unknown. To test the idea that circulating factors mediate age-dependent changes in peripheral rhythms, we compared the ability of human serum from young and old individuals to synchronize circadian rhythms in culture. We collected blood from apparently healthy young (age 25–30) and old (age 70–76) individuals at 14:00 and used the serum to synchronize cultured fibroblasts. We found that young and old sera are equally competent at initiating robust ~24 hr oscillations of a luciferase reporter driven by clock gene promoter. However, cyclic gene expression is affected, such that young and old sera promote cycling of different sets of genes. Genes that lose rhythmicity with old serum entrainment are associated with oxidative phosphorylation and Alzheimer’s Disease as identified by STRING and IPA analyses. Conversely, the expression of cycling genes associated with cholesterol biosynthesis increased in the cells entrained with old serum. Genes involved in the cell cycle and transcription/translation remain rhythmic in both conditions. We did not observe a global difference in the distribution of phase between groups, but found that peak expression of several clock-controlled genes (PER3, NR1D1, NR1D2, CRY1, CRY2, and TEF) lagged in the cells synchronized ex vivo with old serum. Taken together, these findings demonstrate that age-dependent blood-borne factors affect circadian rhythms in peripheral cells and have the potential to impact health and disease via maintaining or disrupting rhythms respectively.